ACTB promotes ESCC progression by regulating the AKT–mTOR signaling pathway through an m6A-dependent mechanism
- 1Department of Oncology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian China
- 2Department of Radiation Oncology, Peking University Third Hospital, Beijing, China
- 3Department of Radiology, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital, Zhengzhou, China
Abstract
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and the upstream regulatory mechanisms driving oncogenic signaling remain insufficiently defined. In this study, we identify a previously unrecognized nuclear function of the cytoskeletal protein ACTB in promoting ESCC progression. We show that ACTB translocates to the nucleus and directly binds to the promoter of the m6A reader gene YTHDC2, transcriptionally activating its expression. YTHDC2, in turn, binds to m6A-modified sites on AKT mRNA, preventing its degradation and enhancing its stability. This results in sustained activation of the PI3K–AKT–mTOR signaling pathway, a key oncogenic cascade that promotes tumor growth and survival. Integrated CUT&Tag and RNA-seq analyses revealed a direct ACTB–YTHDC2 transcriptional axis, while RNA immunoprecipitation and MeRIP-qPCR confirmed YTHDC2–AKT interaction via m6A recognition. Functional assays in ESCC cell lines, patient-derived organoids, and xenograft mouse models demonstrated that both ACTB and YTHDC2 are essential for ESCC proliferation and tumorigenicity. Notably, pharmacological inhibition of mTOR with rapamycin effectively suppressed ACTB-driven tumor phenotypes in vitro and in vivo, supporting the therapeutic relevance of this signaling axis. Together, our findings define a novel ACTB–YTHDC2–AKT–mTOR regulatory network that integrates transcriptional and epitranscriptomic control in ESCC. This study reveals a noncanonical nuclear role for ACTB and identifies a mechanistically tractable pathway that may be exploited for targeted therapy in ACTB-driven esophageal cancer.
Related
- Mechanism of luteolin in treating chronic heart failure by regulating HIF-1 signaling pathway-mediated mitochondrial damage to inhibit cardiomyocyte apoptosis
- VIRMA-associated SRD5A2 downregulation promotes BPH progression through ERα-CREB5-dependent epithelial plasticity
- IL10RB-AS1 promotes pro-caspase-1-dependent pyroptosis via regulating the oligomerization and nucleation of CARD8 C-terminal domain to suppress acute myeloid leukemia
- ALKBH8 promotes acute myeloid leukemia progression by coupling codon-dependent translation elongation to mRNA stability
- Ubiquitin-conjugating enzyme E2S promotes the progression of lung adenocarcinoma through the NF-κB/GATM signaling axis
BibTeX
@article{jiang2026actb,
title = {{ACTB promotes ESCC progression by regulating the AKT–mTOR signaling pathway through an m6A-dependent mechanism}},
author = {Yunshan Jiang and Dan Zhao and Dongxia Liao and Fengling Yang and Canyang Lin and Pengfei Liu and Zheyuan Chen and Fang Shaobo and Xiaoxue Deng and Xiaolei Ni and Baoling Guo},
journal = {Oncogene},
year = {2026},
month = sep,
doi = {10.1038/s41388-026-03995-3},
url = {https://doi.org/10.1038/s41388-026-03995-3},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - ACTB promotes ESCC progression by regulating the AKT–mTOR signaling pathway through an m6A-dependent mechanism
AU - Yunshan Jiang
AU - Dan Zhao
AU - Dongxia Liao
AU - Fengling Yang
AU - Canyang Lin
AU - Pengfei Liu
AU - Zheyuan Chen
AU - Fang Shaobo
AU - Xiaoxue Deng
AU - Xiaolei Ni
AU - Baoling Guo
PY - 2026
DA - 2026/09/30
JO - Oncogene
DO - 10.1038/s41388-026-03995-3
UR - https://doi.org/10.1038/s41388-026-03995-3
AB - Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and the upstream regulatory mechanisms driving oncogenic signaling remain insufficiently defined. In this study, we identify a previously unrecognized nuclear function of the cytoskeletal protein ACTB in promoting ESCC progression. We show that ACTB translocates to the nucleus and directly binds to the promoter of the m6A reader gene YTHDC2, transcriptionally activating its expression. YTHDC2, in turn, binds to m6A-modified sites on AKT mRNA, preventing its degradation and enhancing its stability. This results in sustained activation of the PI3K–AKT–mTOR signaling pathway, a key oncogenic cascade that promotes tumor growth and survival. Integrated CUT&Tag and RNA-seq analyses revealed a direct ACTB–YTHDC2 transcriptional axis, while RNA immunoprecipitation and MeRIP-qPCR confirmed YTHDC2–AKT interaction via m6A recognition. Functional assays in ESCC cell lines, patient-derived organoids, and xenograft mouse models demonstrated that both ACTB and YTHDC2 are essential for ESCC proliferation and tumorigenicity. Notably, pharmacological inhibition of mTOR with rapamycin effectively suppressed ACTB-driven tumor phenotypes in vitro and in vivo, supporting the therapeutic relevance of this signaling axis. Together, our findings define a novel ACTB–YTHDC2–AKT–mTOR regulatory network that integrates transcriptional and epitranscriptomic control in ESCC. This study reveals a noncanonical nuclear role for ACTB and identifies a mechanistically tractable pathway that may be exploited for targeted therapy in ACTB-driven esophageal cancer.
SN - 0950-9232
SN - 1476-5594
ER -